516 related articles for article (PubMed ID: 23602600)
21. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
22. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
Wnorowski AM; de Souza A; Chachoua A; Cohen DE
Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer].
Wang MZ; Zhang XT; Zhang XY; Zhang L; Zhong W; Xu LY; Li LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr; 32(2):151-6. PubMed ID: 20450543
[TBL] [Abstract][Full Text] [Related]
24. [Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Sun C; Zhang X; Chen Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Dec; 32(12):1839-40, 1 p following 1840. PubMed ID: 23268424
[TBL] [Abstract][Full Text] [Related]
25. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Bezjak A; Tu D; Seymour L; Clark G; Trajkovic A; Zukin M; Ayoub J; Lago S; de Albuquerque Ribeiro R; Gerogianni A; Cyjon A; Noble J; Laberge F; Chan RT; Fenton D; von Pawel J; Reck M; Shepherd FA;
J Clin Oncol; 2006 Aug; 24(24):3831-7. PubMed ID: 16921034
[TBL] [Abstract][Full Text] [Related]
26. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
27. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases.
Chanprapaph K; Pongcharoen P; Vachiramon V
Indian J Dermatol Venereol Leprol; 2015; 81(5):547. PubMed ID: 25994883
[TBL] [Abstract][Full Text] [Related]
30. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
31. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
[TBL] [Abstract][Full Text] [Related]
32. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
34. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
[TBL] [Abstract][Full Text] [Related]
35. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Apr; 72(1):3-8. PubMed ID: 21216488
[TBL] [Abstract][Full Text] [Related]
36. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Heigener DF; Wu YL; van Zandwijk N; Mali P; Horwood K; Reck M
Lung Cancer; 2011 Nov; 74(2):274-9. PubMed ID: 21439671
[TBL] [Abstract][Full Text] [Related]
37. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
[TBL] [Abstract][Full Text] [Related]
38. Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B; Muller A; Boelke E; Budach W
J Clin Oncol; 2007 Oct; 25(29):4697-8; author reply 4698-9. PubMed ID: 17925571
[No Abstract] [Full Text] [Related]
39. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
40. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]